会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 21. 发明授权
    • Heregulin antagonists and methods for their use
    • 促胰岛素拮抗剂及其使用方法
    • US6143740A
    • 2000-11-07
    • US308396
    • 1999-08-16
    • Dajun YangShaomeng WangAlan P. KozikowskiMarc E. Lippman
    • Dajun YangShaomeng WangAlan P. KozikowskiMarc E. Lippman
    • C07D498/18A61K31/34A61K31/395A61K31/495A61K31/496A61K31/551A61K31/655A61P35/00A61P43/00C07D498/08A61K31/33C07K1/00C07K16/00
    • A61K31/708A61K31/395A61K31/495A61K31/496A61K31/551A61K31/655A61K31/704A61K31/7076C07D498/08
    • The invention provides a method of inhibiting cancer cell growth, and thereby of treating cancer comprising administering to a mammal afflicted with cancer an effective amount of the compound of formula (I), wherein the variables of R.sub.1, and R.sub.2 have the meanings defined in the specification. The present invention also provides novel compounds of formula (I) as well as novel pharmaceutical compositions and intermediates useful for preparing compounds of formula (I). The figure illustrates the structure and binding activity of compounds of the invention and some of the rifamycin analogs.______________________________________ ##STR1## ______________________________________ Compounds R.sub.1 = ______________________________________ A1 --OH A2 --OH A3 --OH A4 --OH A5 --OH A6 --OH A7 --OH - A8 ##STR2## ______________________________________ Compounds R.sub.2 = ______________________________________ A1 #STR3## - A2 #STR4## - A3 #STR5## - A4 #STR6## - A5 #STR7## - A6 #STR8## - A7 #STR9## - A8 --H ______________________________________ Compounds IC.sub.50 (1) IC.sub.50 (2) ______________________________________ A1 10 uM 1 uM A2 10 uM 3 uM A3 10 uM 3 uM A4 50 uM 5 uM A5 >500 uM >50 uM A6 >500 uM >50 uM A7 >200 uM >50 uM A8 >500 M >50 uM ______________________________________
    • PCT No.PCT / US97 / 21474 Sec。 371日期1999年8月16日 102(e)1999年8月16日PCT 1997年11月19日PCT公布。 第WO98 / 21956号公报 日期1998年5月28日本发明提供抑制癌细胞生长,从而治疗癌症的方法,包括向患有癌症的哺乳动物施用有效量的式(I)化合物,其中R1和R2的变量具有 在本说明书中定义的含义。 本发明还提供新的式(I)化合物以及可用于制备式(I)化合物的新型药物组合物和中间体。 该图示出了本发明化合物和一些利福霉素类似物的结构和结合活性。 - 化合物R1 = -Al-OH-A2-OH-A3-OH-A4-OH-A5-OH-A6-OH-A7 -OH - - A8化合物R2 = 图像 - - A2 - - A3 - - A4 GE> - - A7 - - A8 -H - 化合物IC50(1)IC50(2) - A1 10 uM 1 uM - A2 10 uM 3 uM - A3 10 uM 3 uM - A4 50 uM 5 uM - A5> 500 uM> 50 uM - A6> 500 uM> 50 uM - A7> 200 uM> 50 uM - A8> 500 M> 50 uM -
    • 23. 发明授权
    • ErbB-2 selective small molecule kinase inhibitors
    • ErbB-2选择性小分子激酶抑制剂
    • US07427689B2
    • 2008-09-23
    • US10343267
    • 2001-07-30
    • Shaomeng WangDajun YangIstvan Enyedy
    • Shaomeng WangDajun YangIstvan Enyedy
    • C07C205/00
    • A61K31/216A61K31/00A61K31/192
    • A novel method for erbB-2 kinase inhibition by compounds identifies through computational modeling and data processing and/or rational and de novo drug design is provided the compounds bind erbB-2 kinase molecules and which can be used as erbB-2 kinase agonists or antagonists. These compounds are useful especially in the treatment of cancer, particularly breast cancer, and can be used alone or in combination with other chemotherapeutic agents, particularly with hercetin, a humanized anti-HER-2 antibody, or with radiation therapy. A specific compound which is exemplified is “compound B17”=methyl-(p-nitrophenyl)-2-propynoate.
    • 化合物的erbB-2激酶抑制的新方法通过计算建模和数据处理鉴定,和/或合理和从头药物设计提供了化合物结合erbB-2激酶分子,并且其可以用作erbB-2激酶激动剂或拮抗剂 。 这些化合物特别用于治疗癌症,特别是乳腺癌,并且可以单独使用或与其它化学治疗剂,特别是与赫氏原,人源化抗HER-2抗体或放射治疗组合使用。 例示的具体化合物是“化合物B17”=甲基 - (对硝基苯基)-2-丙炔酸酯。
    • 25. 发明申请
    • PHENYLALANINE DERIVATIVES
    • 苯乙烯胺衍生物
    • US20070219194A1
    • 2007-09-20
    • US11749499
    • 2007-05-16
    • Terrence BurkeYang GaoZhu-jun YaoDajun Yang
    • Terrence BurkeYang GaoZhu-jun YaoDajun Yang
    • A61K31/5377
    • C07K5/0819A61K38/00C07C271/22C07D265/32C07K5/0812C07K5/0827
    • The present invention provides phenylalanine derivatives that inhibit SH2 domain binding with a phosphoprotein. These derivatives include compounds of the formula: W—Y-(AA)n-Z wherein n is 0 to 15; Y is a phenylalanyl radical having a phenyl ring, an amine end, and a carboxyl end, the phenyl ring having one or more substituents, e.g., hydroxyl, carboxyl, formyl, carboxyalkyl, carboxyalkyloxy, dicarboxyalkyl, dicarboxyalkyloxy, dicarboxyhaloalkyl, dicarboxyhaloalkyloxy, and phosphonoalkyl, or phosphonohaloalkyl; W is a moiety attached to the nitrogen of Y and is, e.g., alkylcarbonyl, oxalyl, alkylaminooxalyl, arylaminooxalyl, arylalkylaminooxalyl, or alkoxyoxalyl; AA is an amino acid, the amine end of which is attached to the carboxyl end of Y; and Z is an arylalkylamino or arylheterocyclyl alkylamino; or a salt thereof; with the proviso that W is not arylalkylamino when the phenyl ring of phenylalanyl contains a phosphonoalkyl or phosphonohaloalkyl substituent at a position para to the alkylamido group and the ortho and meta positions are unsubstituted. The present invention further provides precursors suitable for preparing the phenylalanine derivatives and a method for the preparation of the precursors. The present invention further provides conjugates comprising a precursor and a conjugant that are covalently linked. These conjugates have biological and/or pharmacological properties.
    • 本发明提供抑制与磷蛋白结合的SH2结构域的苯丙氨酸衍生物。 这些衍生物包括下式的化合物:其中n为0至15的W-Y-(AA)n-n -Z; Y是具有苯环,胺末端和羧基端的苯丙氨酰基,苯环具有一个或多个取代基,例如羟基,羧基,甲酰基,羧基烷基,羧基烷氧基,二羧基烷基,二羧基烷氧基,二羧基卤代烷基,二羧基卤代烷氧基和膦酰基烷基 ,或膦酰卤代烷基; W是连接到Y的氮的部分,例如烷基羰基,草酰基,烷基氨基草酰基,芳基氨基草酰基,芳基烷基氨基草酰基或烷氧基草酰基; AA是氨基酸,其末端连接到Y的羧基末端; Z是芳基烷基氨基或芳基杂环基烷基氨基; 或其盐; 条件是当苯丙氨酰基的苯环在烷基酰氨基的对位位置含有膦酰基烷基或膦酰卤代烷基取代基时,W不是芳烷基氨基,邻位和间位是未取代的。 本发明还提供适用于制备苯丙氨酸衍生物的前体和前体的制备方法。 本发明进一步提供包含共价连接的前体和共轭物的缀合物。 这些缀合物具有生物学和/或药理学性质。